{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:36:31Z","timestamp":1793219791921,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100020950","name":"National Science and Technology Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012544","name":"China Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009330","name":"Medical Science and Technology Foundation of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.critrevonc.2026.105646","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:11:12Z","timestamp":1792167072000},"page":"105646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cardiovascular toxicities associated with immune checkpoint inhibitors: Clinical phenotypes, mechanisms, diagnosis, and management\u2014A narrative review"],"prefix":"10.1016","volume":"228","author":[{"given":"Shuhong","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoman","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilu","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Jan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.critrevonc.2026.105646_bib1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","article-title":"Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis","volume":"75","author":"Awadalla","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7937","key":"10.1016\/j.critrevonc.2026.105646_bib2","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105646_bib3","article-title":"Abnormal gut microbiota may cause PD-1 inhibitor-related cardiotoxicity via suppressing regulatory T cells","volume":"15","author":"Cao","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105646_bib4","unstructured":"ClinicalTrials.gov. Abatacept in immune checkpoint inhibitor myocarditis (ATRIUM). NCT05335928. Updated August 20, 2026. Accessed September 26, 2026. https:\/\/clinicaltrials.gov\/study\/NCT05335928."},{"key":"10.1016\/j.critrevonc.2026.105646_bib5","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3390\/cells14171397","article-title":"Distinct inflammatory responses of hiPSC-derived endothelial cells and cardiomyocytes to cytokines involved in immune checkpoint inhibitor-associated myocarditis","volume":"14","author":"Conte","year":"2025","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105646_bib6","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2459\/JCM.0000000000000232","article-title":"Chemotherapy cardiotoxicity: cardioprotective drugs and early identification of cardiac dysfunction","volume":"17","author":"Di Lisi","year":"2016","journal-title":"J. Cardiovasc. Med."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105646_bib7","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105646_bib8","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMc1903064","article-title":"Alemtuzumab for immune-related myocarditis due to PD-1 therapy","volume":"380","author":"Esfahani","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105646_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002771","article-title":"Pericardial disease in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gong","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105646_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.24168","article-title":"Troponin screening and major cardiovascular adverse events during immune checkpoint inhibitor therapy","volume":"9","author":"Hamdi","year":"2026","journal-title":"JAMA Netw. Open."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105646_bib11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/jamaoncol.2025.4543","article-title":"Immune checkpoint inhibitor-associated cardiovascular toxic effects: international cardio-oncology society position statement","volume":"12","author":"Herrmann","year":"2026","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105646_bib12","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.critrevonc.2026.105646_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2024.108912","article-title":"Chemokine receptor PET imaging: bridging molecular insights with clinical applications","volume":"134-135","author":"Hunter","year":"2024","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.critrevonc.2026.105646_bib14","first-page":"84","article-title":"Clonal hematopoiesis of indeterminate potential is associated with increased risk of immune checkpoint inhibitor myocarditis in a prospective study of a cardio-oncology cohort","volume":"10","author":"Jaber Chehayeb","year":"2024","journal-title":"Cardiooncology"},{"key":"10.1016\/j.critrevonc.2026.105646_bib15","doi-asserted-by":"crossref","first-page":"7809","DOI":"10.3390\/jcm14217809","article-title":"Comparison of immune checkpoint inhibitor myocarditis and non-ICI myocarditis using cardiovascular magnetic resonance: a single-centre retrospective observational study","volume":"14","author":"Jacobs","year":"2025","journal-title":"J. Clin. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105646_bib16","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1161\/CIRCRESAHA.124.324260","article-title":"Visualizing immune checkpoint inhibitors derived inflammation in atherosclerosis","volume":"135","author":"Lou","year":"2024","journal-title":"Circ. Res."},{"key":"10.1016\/j.critrevonc.2026.105646_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010127","article-title":"Targeting the NLRP3 inflammasome abrogates cardiotoxicity of immune checkpoint blockers","volume":"13","author":"Lu","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105646_bib18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.21037\/tlcr-2025-aw-1252","article-title":"Development and external validation of a multivariable nomogram for predicting severe immune checkpoint inhibitor-associated myocarditis in advanced lung cancer","volume":"15","author":"Luan","year":"2026","journal-title":"Transl. Lung Cancer Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105646_bib19","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the HFA in collaboration with IC-OS","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"41","key":"10.1016\/j.critrevonc.2026.105646_bib20","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with EHA, ESTRO, and IC-OS","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105646_bib21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.122.062551","article-title":"Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis","volume":"149","author":"Ma","year":"2024","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105646_bib22","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105646_bib23","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1161\/CIRCULATIONAHA.125.076976","article-title":"CXCR6+ T cells drive immune checkpoint inhibitor myocarditis","volume":"153","author":"Munir","year":"2026","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105646_bib24","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamaoncol.2024.3065","article-title":"Herrmann J. Immune checkpoint inhibitor-induced cardiotoxicity: a systematic review and meta-analysis","volume":"10","author":"Nielsen","year":"2024","journal-title":"JAMA Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105646_bib25","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105646_bib26","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.125.041680","article-title":"Diagnostic and prognostic value of high-sensitivity troponin T for cardiovascular outcomes in patients receiving immune checkpoint inhibitor therapy","volume":"15","author":"Pereyra Pietri","year":"2026","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.critrevonc.2026.105646_bib27","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.3390\/cells9091987","article-title":"Antibody-mediated inhibition of CTLA4 aggravates atherosclerotic plaque inflammation and progression in hyperlipidemic mice","volume":"9","author":"Poels","year":"2020","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105646_bib28","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jaccao.2020.08.007","article-title":"Immune checkpoint inhibitor therapy aggravates T cell-driven plaque inflammation in atherosclerosis","volume":"2","author":"Poels","year":"2020","journal-title":"JACC CardioOncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105646_bib29","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/eurheartj\/ehaf315","article-title":"Immune checkpoint inhibitor-associated myocarditis: a novel risk score","volume":"47","author":"Power","year":"2026","journal-title":"Eur. Heart J."},{"issue":"6382","key":"10.1016\/j.critrevonc.2026.105646_bib30","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105646_bib31","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105646_bib32","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/jamacardio.2025.3369","article-title":"Clonal hematopoiesis and risk of new-onset myocarditis and pericarditis","volume":"10","author":"Schuermans","year":"2025","journal-title":"JAMA Cardiol."},{"issue":"40","key":"10.1016\/j.critrevonc.2026.105646_bib33","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1093\/eurheartj\/ehaf192","article-title":"2025 ESC Guidelines for the management of myocarditis and pericarditis","volume":"46","author":"Schulz-Menger","year":"2025","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105646_bib34","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jacc.2021.01.050","article-title":"Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor-associated myocarditis","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105646_bib35","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.critrevonc.2026.105646_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114263","article-title":"Immune checkpoint inhibitor induces cardiac injury by impairing efferocytosis of macrophages via MerTK cleavage","volume":"150","author":"Zhang","year":"2025","journal-title":"Int. Immunopharmacol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:30:09Z","timestamp":1793219409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826005330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":36,"alternative-id":["S1040842826005330"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105646","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular toxicities associated with immune checkpoint inhibitors: Clinical phenotypes, mechanisms, diagnosis, and management\u2014A narrative review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105646","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105646"}}